Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone Receptor Positive Breast Cancer”

381 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 381 results

Testing effectiveness (Phase 2)Study completedNCT00186121
What this trial is testing

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Who this might be right for
Breast Cancer
Stanford University 35
Testing effectiveness (Phase 2)Ended earlyNCT00570258
What this trial is testing

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Who this might be right for
Metastatic Breast Cancer
University of Arkansas 27
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Testing effectiveness (Phase 2)Study completedNCT00405938
What this trial is testing

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms
SCRI Development Innovations, LLC 79
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Testing effectiveness (Phase 2)Ended earlyNCT00903006
What this trial is testing

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 11
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT00082810
What this trial is testing

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IIIB Breast Cancer+2 more
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Study completedNCT02102490
What this trial is testing

Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 132
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)Study completedNCT00274469
What this trial is testing

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 205
Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Testing effectiveness (Phase 2)Looking for participantsNCT07340541
What this trial is testing

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Who this might be right for
Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center 700
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)UnknownNCT01266213
What this trial is testing

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Who this might be right for
Metastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal
Samsung Medical Center 147
Testing effectiveness (Phase 2)WithdrawnNCT01288092
What this trial is testing

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04460430
What this trial is testing

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 12
Next Page